Earlier this week, Shanghai Henlius Biotech, Inc. announced that it has entered into a semi-exclusive license agreement with Abbott Operations Uruguay S.R.L. for the commercialization of HANLIKANG (rituximab) and HANQUYOU (trastuzumab, trade name in Europe: Zercepac^®), two products developed by Henlius, in Brazil.  According to the announcement, Abbott will pay Henlius an up-front fee of $3 million (USD), and up to an aggregate of $1.4 million (USD) for certain regulatory milestone payments.  Henlius states that the agreement “will help the company to further expand the overseas market of” the two products subject to the license.

[View source.]